Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2018

View Archived Issues

Etanercept biosimilar approved in Japan

Phase III CORAIL study of Zepsyre does not meet primary endpoint

MNI-1038 tracer shows promise as PET-based diagnostic for neurodegeneration

FDA issues complete response letter for CAM-2038 NDA for opioid use disorder

Phase III HELIOS trial of ASP-0113 misses endpoints

FDA clears Zealand Pharma to begin phase III trials of dasiglucagon for congenital hyperinsulinism

Sanofi set to acquire Bioverativ

Merck & Co. and Idenix describe novel HCV RNA polymerase NS5B inhibitors

The University of Kentucky patents prostaglandin E synthase inhibitors

Avacta and OncoSec Medical establish research collaboration

Novartis to transition Arzerra for CLL to compassionate use programs outside U.S.

HDAC/histone-lysine N-methyltransferase EHMT2 inhibitors discovered at Georgia State University

Roche identifies novel anti-influenza compounds

St Jude Children's Research Hospital patents new anti-CD7 chimeric antigen receptors

[18F]THK-5351 found useful for brain injury imaging

New phase I/II trial studies mRNA vaccine BI-1361849 with checkpoint inhibitors in NSCLC

Phase II study finds sotatercept effective for anemia in lower-risk myelodysplastic syndromes

FDA grants priority review to Darzalex sBLA in newly diagnosed multiple myeloma

Akeso Bio studies AK-105 in phase I for advanced solid tumors

New phase III trial explores use of BAX-111 in pediatric severe hereditary von Willebrand disease

Dupixent approved in Japan for treatment of atopic dermatitis

Moderna Therapeutics begins phase I trial of mRNA-1653

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...